Viveve Medical Inc. Down 4.74% To $0.50 After Earnings Beat

Viveve Medical Inc. (VIVE) said after close Thursday that it lost $0.59 per share in quarter three 2022.

On the revenue line, the company reported $1.7 million, missing estimates by $16 thousand.

In the same quarter a year ago, the company lost $0.67 per share on revenue of $1.6 million.

The stock is down 4.74% to $0.50 after the report.

Despite revenues increasing, earnings decreased, signaling a decline in profit margins.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 33. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.